Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk has been one of the chief beneficiaries ... Like those injections, the new drug targets gut hormone GLP-1 but additionally mimics amylin, a hormone released by the pancreas that ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

European equity markets are set to open higher on Friday to cap a positive week for stocks. The U.K.'s FTSE 100 is set to ...

Novo Nordisk ... long-term earnings growth of about 19%, we may be approaching the point where all the "bad" news will be "priced in," and there's nowhere left for Novo Nordisk stock to go but ...

This difference is crucial, because making insulin means biologically reproducing a human hormone ... growth market, but of the two I believe the greatest potential at the moment is in Novo Nordisk.

and human growth hormone. While Novo Nordisk has built itself into a pharmaceutical giant, it has seriously run afoul of regulatory laws on several occasions. Novo Nordisk’s practices have ...